Department of Orthopaedic Surgery, Polyclinique de la Thiérache, Rue du Dr Koral, 59212, Wignehies, France.
AMR Advanced Medical Research, Männedorf, Switzerland.
J Orthop Surg Res. 2021 Nov 27;16(1):697. doi: 10.1186/s13018-021-02846-z.
Renal patients are at high risk of blood transfusion following major orthopaedic surgery. A variety of patient blood management (PBM) policies have been proposed to reduce the rate of transfusions. The aim of this observational study was to assess the performance of an adjusted PBM protocol in patients with chronic kidney disease (CKD) undergoing elective total hip arthroplasty (THA).
A total of 1191 consecutive patients underwent elective unilateral THA and took part in an adjusted PBM protocol. The PBM protocol consisted of epoetin (EPO) alfa therapy prescribed by the surgeon, routine administration of tranexamic acid (TXA), an avascular approach to the hip and postoperative prophylaxis of thromboembolism. The performance of this PBM protocol was analysed in patients with a glomerular filtration rate (GFR) below or above 60 ml/min/1.73 m at baseline. Haemoglobin levels were controlled at admission, on postoperative day (POD) 1 and on POD 7 ± 1. A bleeding index (BI) was used as a proxy for blood loss.
In total, 153 patients (12.9%) presented with a modification of diet in renal disease value below 60 at baseline. Of these, 20 (13.1%) received EPO therapy and 120 (78.4%) received TXA. None of the patients received allogenic blood transfusions during the first perioperative week. The mean BI for the entire study population was 2.7 (95% CI 2.6, 2.8). CKD did not exert a significant impact on the BI (p = 0.287). However, it was found that both TXA and EPO therapy significantly lowered the BI (difference, - 0.3, p < 0.001). There were no thromboembolic complications in renal patients who received TXA and/or EPO therapy.
A zero-percent transfusion rate during the first perioperative week is attainable in patients with stage 3 or stage 4 CKD undergoing contemporary elective THA. With the use of a pragmatic blood-sparing protocol, patients with renal dysfunction did not have an increased risk of bleeding and did not have an increased incidence in the rate of perioperative blood transfusions.
肾患者在接受大型骨科手术后有输血的高风险。已经提出了各种患者血液管理(PBM)策略来降低输血率。本观察性研究的目的是评估调整后的 PBM 方案在接受择期全髋关节置换术(THA)的慢性肾脏病(CKD)患者中的表现。
共 1191 例连续患者接受单侧 THA 并参加了调整后的 PBM 方案。PBM 方案包括由外科医生开具的促红细胞生成素(EPO)α治疗、常规给予氨甲环酸(TXA)、髋关节无血管入路和术后预防血栓栓塞。在基线肾小球滤过率(GFR)低于或高于 60 ml/min/1.73 m 的患者中分析该 PBM 方案的性能。血红蛋白水平在入院时、术后第 1 天和第 7 天±1 时进行控制。出血指数(BI)用作失血的替代指标。
共有 153 例(12.9%)患者基线时改良肾脏病饮食研究值低于 60。其中,20 例(13.1%)接受 EPO 治疗,120 例(78.4%)接受 TXA 治疗。在整个围手术期的第一周内,没有患者接受同种异体输血。整个研究人群的平均 BI 为 2.7(95%CI 2.6,2.8)。CKD 对 BI 没有显著影响(p=0.287)。然而,发现 TXA 和 EPO 治疗均显著降低了 BI(差异,-0.3,p<0.001)。接受 TXA 和/或 EPO 治疗的肾患者无血栓栓塞并发症。
在接受当代择期 THA 的 3 期或 4 期 CKD 患者中,在围手术期的第一周内实现零输血率是可行的。使用实用的血液节约方案,肾功能障碍患者没有增加出血风险,也没有增加围手术期输血率。